NASDAQ:WVE - Wave Life Sciences Stock Price, Price Target & More

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) released its earnings results on Wednesday, May, 9th. The company reported ($1.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.36. The business earned $1.42 million during the quarter, compared to analysts' expectations of $6.59 million. Wave Life Sciences had a negative return on equity of 76.93% and a negative net margin of 2,613.03%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Wave Life Sciences.

4 equities research analysts have issued 12 month price targets for Wave Life Sciences' shares. Their predictions range from $40.00 to $65.00. On average, they expect Wave Life Sciences' share price to reach $56.75 in the next twelve months. View Analyst Ratings for Wave Life Sciences.

Some companies that are related to Wave Life Sciences include Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO) and OPKO Health (OPK).

Media stories about WVE stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Wave Life Sciences earned a news sentiment score of 0.17 on Accern's scale. They also gave headlines about the company an impact score of 45.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Wave Life Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (7.69%), BB Biotech AG (3.08%), BlackRock Inc. (3.01%), Eventide Asset Management LLC (1.30%), JPMorgan Chase & Co. (0.54%) and Artal Group S.A. (0.52%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, BlackRock Inc., Point72 Asset Management L.P., Eventide Asset Management LLC, Bailard Inc., Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and A.R.T. Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

WVE stock was bought by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Artal Group S.A., DAFNA Capital Management LLC, BB Biotech AG, Platinum Investment Management Ltd., Redmile Group LLC, Citadel Advisors LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $33.40.

Wave Life Sciences has a market capitalization of $1.11 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]